心臓リモデリングの病態と治療に関する研究

【文献】

• 1. Morishige S, Takahashi-Yanaga F, Ishikane S, Arioka M, Igawa K, Kuroo A, Tomooka K, Shiose A, Sasaguri T. 2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation. Biochem Pharmacol. 2019; 168: 82-90.

  2. Fujita A, Takahashi-Yanaga F, Morimoto S, Yoshihara T, Arioka M, Igawa K, Tomooka K, Hoka S, Sasaguri T. 2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through activation of GSK-3. Hypertens Res. 2017;40:130-139.

  3. Takahashi-Yanaga F Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease. J UOEH. 2018;40(2):147-156.

  4. Mohamed R, Morimoto S, Ibrahim I, Zhan D-Y, Du C-K, Arioka M, Yoshihara T, Takahashi-Yanaga F, Sasaguri T. GSK-3b heterozygous knockout is cardioprotective in a knock-in mouse model of familial dilated cardiomyopathy. Am J Physiol, Heart Circ Physiol 310：H1808-H1815, 2016

  5. Nonaka M, Morimoto S, Murayama T, Kurebayashi N, Li L, Wang Y-Y, Arioka M, Yoshihara T, Takahashi-Yanaga F, Sasaguri T. Stage-dependent benefits and risks of pimobendan in genetic dilated cardiomyopathy mice with progressive heart failure. Br J Pharmacol 172：2369-2382, 2015

  6. Fan X, Takahashi-Yanaga F, Morimoto S, Zhan D-Y, Igawa K, Tomooka K, Sasaguri T. Celecoxib and 2,5-dimethyl- celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited DCM mouse model. J Pharmacol Exp Ther 338：2-11, 2011